| Old Articles: <Older 10231-10240 Newer> |
|---|
 |
The Motley Fool
October 20, 2005
Chuck Saletta |
Dueling Fools: Blue Nile Bear Rebuttal The analysts are overly optimistic with their projection of 30% growth for this diamond e-tailer. Don't be fooled by a shiny rock, or you'll end up paying diamond prices for cubic zirconium shares.   |
The Motley Fool
October 20, 2005
Nathan Parmelee |
Dueling Fools: Blue Nile Bull Like the perfectly cut diamonds it sells, Blue Nile is something special. The premier online jeweler isn't cheap, but it is cheaper than its P/E would lead you to believe. |
The Motley Fool
October 20, 2005
Chuck Saletta |
Dueling Fools: Blue Nile Bear The jewelry e-tailer drastically trails the competition from a value investor's perspective. Looking at the company from a risk-adjusted reward perspective, Blue Nile is simply tilted way too far towards risk, with not enough opportunity for reward. |
The Motley Fool
October 20, 2005
Chuck Saletta |
Avoid the Value Traps Just because a company's shares may move up as well as down, that doesn't mean the company is a worthy investment. Regardless of what they look like on the surface, some stocks still aren't values. |
The Motley Fool
October 20, 2005
Rich Smith |
LabCorp: Boring Can Be Good The company is firmly on track toward this year's goal of $440 million to $465 million in free cash flow. Should the company hit even the low end of that guidance, it would be valued at under 16 times FCF, smack dab in between its projected growth rate and its return on equity. |
The Motley Fool
October 20, 2005
Stephen D. Simpson |
Pfizer Fizzles Disappointing guidance could have this giant pharmaceutical company retesting its lows. This is likely a good time for long-termers to do their due diligence, since they'll probably have some time to get into the stock. |
The Motley Fool
October 20, 2005
Stephen D. Simpson |
Baxter Needs Growth Infusion This is a fine health-care company, but a sluggish top line suggests there are limits to how far it can go. Trading at nearly 20 times forward earnings, it seems like expectations of a growth revival are already in the stock. |
The Motley Fool
October 20, 2005
Seth Jayson |
Kodak's Insincere Smile Despite the corporate spin, Kodak continues to fade. Investors, take note. |
The Motley Fool
October 20, 2005
Stephen D. Simpson |
Industrious Profits for Ingersoll-Rand This industrial conglomerate still looks attractively priced. |
The Motley Fool
October 20, 2005
Stephen D. Simpson |
Wide Eyes at Alcon Excellent margin performance fueled exceptional growth for this eye-care titan. This is a strong and valuable cash-producing franchise, and it deserves a premium valuation -- but how much of a premium? |
| <Older 10231-10240 Newer> Return to current articles. |
